Neurons degenerate and die as a result or cause of Alzheimer's Disease. Neurotrophic factors (NT) are molecules that can support the survival of neurons and their exogenous delivery to the aged brain may prevent, retard, or reverse neuronal degeneration. However, since the NTs are large molecules that do not easily pass the blood-brain barrier, they must be delivered directly to the brain. Intraventricular infusion results in the dilution of the NT in the intraventricular fluid; this method of delivery has the disadvantage of delivering the NT throughout the brain to areas that may not need the NT. Furthermore, the infusion method requires an indwelling cannula and an externally attached pump as a reservoir, an arrangement which is susceptible to infection. We have developed a method to implant autologous cells, genetically engineered to make and secrete NTs, directly into the area of the brain that can benefit from NT augmentation. We plan to further develop this strategy using nerve growth factor (NGF) as the NT and cholinergic neurons as the target neurons, as these are the neurons that degenerate with aging. We will study the long- term survival of primary fibroblasts genetically engineered to make and secrete NGF and their effect on cholinergic neuron survival and other morphological parameters. In addition, we will evaluate the effects of this therapeutic approach on cognitive behavior in aged, cognitively impaired rats. We are also studying other NTs, including BDNF, NT-3 and bFGF. In the future, we will expand on the basic strategy of gene delivery, using these trophic factors separately or in combination. These studies will provide an understanding of the role that these trophic factors play in neuronal and cognitive decline with age and will contribute to the continued development of the gene transfer/intracerebral grafting technique as an approach to the treatment of cognitive dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010435-04
Application #
3746190
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Nagahara, Alan H; Wilson, Bayard R; Ivasyk, Iryna et al. (2018) MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates. Gene Ther 25:104-114
Chen, Zhijiang; Donnelly, Christopher R; Dominguez, Bertha et al. (2017) p75 Is Required for the Establishment of Postnatal Sensory Neuron Diversity by Potentiating Ret Signaling. Cell Rep 21:707-720
Hirai, Maretoshi; Arita, Yoh; McGlade, C Jane et al. (2017) Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J Clin Invest 127:569-582
Overk, Cassia; Masliah, Eliezer (2017) Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimers Dement 13:183-185
Spencer, Brian; Desplats, Paula A; Overk, Cassia R et al. (2016) Reducing Endogenous ?-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model. J Neurosci 36:7971-84
Xu, Jiqing; de Winter, Fred; Farrokhi, Catherine et al. (2016) Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model. Sci Rep 6:31692
Spencer, Brian; Potkar, Rewati; Metcalf, Jeff et al. (2016) Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. J Biol Chem 291:1905-20
Wang, Ling; Conner, James M; Nagahara, Alan H et al. (2016) Rehabilitation drives enhancement of neuronal structure in functionally relevant neuronal subsets. Proc Natl Acad Sci U S A 113:2750-5
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Kratter, Ian H; Zahed, Hengameh; Lau, Alice et al. (2016) Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest 126:3585-97

Showing the most recent 10 out of 183 publications